María Páez de la Cadena Tortosa-rekin lankidetzan egindako argitalpenak (12)

2022

  1. Evaluation of Blood Soluble CD26 as a Complementary Biomarker for Colorectal Cancer Screening Programs

    Cancers, Vol. 14, Núm. 19

2020

  1. CD26-Related Serum Biomarkers: SCD26 Protein, DPP4 Activity, and Anti-CD26 Isotype Levels in a Colorectal Cancer-Screening Context

    Disease Markers, Vol. 2020

  2. Value of serum NEUROG1 methylation for the detection of advanced adenomas and colorectal cancer

    Diagnostics, Vol. 10, Núm. 7

2018

  1. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples

    Clinical Epigenetics, Vol. 10, Núm. 1

2017

  1. Highly sensitive marker panel for guidance in lung cancer rapid diagnostic units

    Scientific Reports, Vol. 7

  2. Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis

    BMC Cancer, Vol. 17, Núm. 1

2016

  1. Evaluation of serum nucleoside diphosphate kinase A for the detection of colorectal cancer

    Scientific Reports, Vol. 6

2015

  1. Serum sCD26 for colorectal cancer screening in family-risk individuals: Comparison with faecal immunochemical test

    British Journal of Cancer, Vol. 112, Núm. 2, pp. 375-381

2014

  1. Postoperative serum levels of sCD26 for surveillance in colorectal cancer patients

    PLoS ONE, Vol. 9, Núm. 9

2010

  1. Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas

    BMC Cancer, Vol. 10

2009

  1. Soluble CD26 levels and its association to epidemiologic parameters in a sample population

    Disease Markers, Vol. 27, Núm. 6, pp. 311-316

2008

  1. How the measurements of a few serum markers can be combined to enhance their clinical values in the management of cancer

    Anticancer Research, Vol. 28, Núm. 4 C, pp. 2333-2341